Genomic Data Analysis & Interpretation enables researchers to adopt statistical & computational methods to decode the information hidden in DNA sequences. These tools allow clinical experts to understand how DNA differences can affect human health & diseases.
The Global Genomic Data Analysis & Interpretation Market is likely to grow at a CAGR of around 11.10% during the forecast period, i.e., 2022-27, says MarkNtel Advisors. The market growth attributes principally to the burgeoning cancer cases worldwide, encouraging numerous biotechnology companies to develop genomic software solutions for data analysis to help clinicians provide precision oncology treatments.
Moreover, the surging applications of Next-Generation Sequencing (NGS) in cancer research, declining costs of sequencing, and the mounting number of genomic research initiatives by both emerging & developed countries are other prominent factors expected to drive the market over the forecast years, further states the research report, "Global Genomic Data Analysis & Interpretation Market Analysis, 2022."
|Study Period||Historical Data: 2017-20|
|Base Year: 2021|
|Forecast Period: 2022-27|
|Regions Covered||North America: USA, Canada, Mexico|
|Europe: Germany, UK, France, Italy, Spain, The Netherlands|
|Asia-Pacific: China, India, Japan, South Korea, Australia and Others|
|South America: Brazil, and Others|
|Middle East & Africa: UAE, Saudi Arabia, South Africa|
|Key Companies Profiled||Agilent Technologies Inc., ThermoFisher Scientific, Asuragen Inc., BGI Genomics Co., Ltd, 10X Genomics Inc., Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd, DNASTAR, Golden Helix Inc., Illumina Inc., Oxford Nanopore Technologies Inc., Pacific Biosciences of California Inc., Partek Inc., QIAGEN NV, SoftGenetics LLC|
|Unit Denominations||USD Million/Billion|
Impact of Covid-19 on the Global Genomic Data Analysis & Interpretation Market